



AMP Molecular Pathology Economics Summit

September 20, 2019 • Washington, D.C.

Preliminary Agenda

Program and Goals

Numerous studies have identified economic issues as a primary impediment to the more effective use of molecular diagnostics in advancing groundbreaking, cost effective patient care. Join the Association for Molecular Pathology (AMP) for an exclusive and interactive discussion of the issues from multiple stakeholder perspectives and have the opportunity to shape the future of this critical and cutting edge space. During the summit all participants, through structured and interactive sessions, will have the opportunity to share perspectives, be educated about the unique challenges facing key influential stakeholders, and explore how diverse and aligned groups can best collaborate to improve patient access to essential molecular testing.

Thursday, September 19, 2019

6:30 pm

AMP Corporate Advisory Council Dinner

*The Conrad Washington D.C., Canvas, Level 2
950 New York Ave. NW
Washington, DC, 20001*

AMP invites members of our 2019 Corporate Advisory Council (CAC) to join us for dinner and discussion on the evening of Thursday, September 19th. Representatives from AMP Corporate Advisory Council member companies will join members of the AMP Economic Affairs Committee for dinner and a high-level discussion of AMP and CAC member company policy and advocacy priorities with the goal of identifying areas where we can work together.

This event is by invitation only. If you would like to learn more about this program and how you can join the AMP Corporate Advisory Council, please contact AMP's Director of Strategic Development, Laurie Menser at lmenser@amp.org.

Main Program

Friday, September 20, 2019

7:30 am

Registration and Breakfast

*The Conrad Washington D.C., Conservatory Ballroom A/B, Level 2
950 New York Ave. NW
Washington, DC, 20001*

8:00 am

Welcome and Opening Remarks

Speaker: **Samuel Caughron**, MD, Chair, AMP Economic Affairs Committee, *MAWD Pathology Group, P.A.*

8:15 am

Real World Perspectives from Key Stakeholders: Challenges and Opportunities in Molecular Diagnostics

Facilitator: **Amy Miller**, PhD

Multiple stakeholders from different industries are affected by the economic challenges plaguing clinical molecular diagnostics. Each industry and stakeholder is uniquely impacted, but there is common alignment around an interest in improving the overall economics for diagnostic testing. Advances in diagnostic testing and closely related therapies are driving precision medicine, while at the same time continuing to challenge current paradigms for molecular diagnostic coding, coverage and reimbursement. During the morning session, a series of roundtable discussions will be held, each focused on a specific stakeholder perspective including clinical laboratories, pharmaceutical companies, in vitro diagnostic manufacturers, and patient advocacy groups. Interactive candid discussions will explore the unique challenges confronting each of these stakeholder groups, with the ultimate goal of mutual understanding and identification of common areas in which to assign resources to improve the economics in pursuit of best patient care.

Pre-summit contemplation of the following questions will assist in framing the conversations:

- What are the biggest economic issues in molecular diagnostics that are barriers for your organization or members? Consider commenting on issues such as:
 - PAMA reform; Laboratory Benefit Managers; coding; NCCI edits; National Coverage Determination for Next Generation; coverage criteria (*i.e.*, “clinical utility”); Sequencing for Advanced Cancer, etc.

- Are there aspects of molecular diagnostic testing reimbursement where stakeholders have been their “own worst enemy?”
- Within the stakeholder community, where is there the biggest disconnect between established reimbursement policy and actual clinical practice? What negative impact has it had?
- How is the regulatory landscape affecting laboratory economics?

10:00 am

Coffee Break

10:15 am

Panel Discussion: Defining Key Themes

Facilitator: **Amy Miller**, PhD

The facilitator will lead a discussion with panel members representing each stakeholder group to unpack the themes revealed in the roundtable discussions.

12:00 pm

Lunch

1:00 pm

AMP Economic Affairs Committee Coding, Coverage and Reimbursement Strategies

Speakers: **Samuel Caughron**, MD, Chair, AMP Economic Affairs Committee, *MAWD Pathology Group, P.A.*

Pranil Chandra, DO, Vice-Chair: Coverage Decisions, AMP Economic Affairs Committee, *PathGroup, LLC*

Anthony Sireci, MD, MSc, Vice-Chair: New Codes and Pricing, AMP Economic Affairs Committee, *Loxo Oncology*

Leaders for the AMP Economic Affairs Committee will present the current and future advocacy resources, strategies, opportunities and objectives of the AMP Economic Affairs Committee in the areas of coding, coverage and pricing. The speakers will highlight past successes and lessons learned through advocacy efforts and answer questions from participants.

1:30 pm

Coffee Break

1:45 pm

Facilitated Discussion: Identifying High Impact Solutions

Facilitator: **Amy Miller**, PhD

Participants will join in discussion on how the themes from the morning session can be addressed through stakeholder’s advocacy activity. The objective of this session is to identify potential policy solutions on which stakeholders can align in allocating resources to improve molecular diagnostic testing coding, coverage, and/or pricing, whether it is through individual or collaborative approaches.

The following questions will assist in framing the conversation:

- Are there achievable novel approaches that should be considered in order to achieve the desired outcomes?
- How can we best work to ensure patient access to molecular diagnostic testing throughout the healthcare system?
- Is it possible to achieve a commitment to action from the stakeholders in the room?

3:00 pm

Closing Remarks and Next Steps

Speaker: **Samuel Caughron, MD**

3:30 pm

Depart

Biographies

Program Chair



Samuel K. Caughron, MD, is the current Chair of AMP’s Economic Affairs Committee, and a member of AMP’s Professional Relations Committee and Board of Directors. Before becoming Chair, Dr. Caughron served on the Economic Affairs Committee as co-chair from 2010-2014, as well as serving on the Nominating Committee from 2012-2014.

In addition to his service to AMP, Dr. Caughron has served on professional pathology and medical committees for the College of American Pathologists, Association of Community Cancer Centers, Missouri Society of Pathology, the Catholic Medical Association Guild-Kansas City, American Pathology Foundation, the Kansas Medicare Carrier Advisory Committee, and the Medicare Evidence Development & Coverage Advisory Committee.

Dr. Caughron is the Chair of Pathology and Laboratory Medical Director for Shawnee Mission Medical Center. Since 2009, Dr. Caughron has also served as the President and CEO of the MAWD Pathology Group and the Founding Director of the MAWD Molecular Laboratory in Kansas City, Missouri. He is Board Certified in Anatomic and Clinical Pathology and Molecular Pathology. Dr. Caughron received his medical degree and did his Anatomic and Clinical Pathology residency at Creighton University Medical Center in Omaha, Nebraska. He completed his Molecular Genetic Pathology fellowship at

Vanderbilt University. After his fellowship, he established and directed a molecular genetic pathology laboratory in Billings, Montana.

Program Facilitator



Amy M. Miller, PhD, is the President and Chief Executive Officer of the Society for Women’s Health Research (SWHR), a nearly 30-year-old nonprofit dedicated to eliminating imbalances in health care for women through science, policy, and education.

Dr. Miller previously worked at the Personalized Medicine Coalition (PMC), where she served as Executive Vice President, working with innovators, scientists, providers, and payers on scientific policy and business challenges impacting personalized medicine.

Before joining PMC, Dr. Miller worked in the office of the Director of the National Institute of Mental Health, where she served as a liaison among the scientific community, the legislative branch, and the consumers of mental health care and their families.

A former American Association for the Advancement of Science Fellow, Dr. Miller also served as a domestic policy advisor to Senator Jay Rockefeller. She began her career as a researcher at the National Institute of Child Health and Human Development (NICHD).

Dr. Miller received a bachelor’s degree from the University of New Orleans and holds a doctoral degree in human development from the University of Connecticut.

About AMP

The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP’s 2,500+ members include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees.

Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing.